Latest News, Grants & Research Reports
Read our latest news, blog posts and research updates right here
BBC Lifeline Appeal
We are honored to announce that Neuroblastoma UK will be featured on the BBC Lifeline Appeal on Sunday, 26 January, at 13.50 on BBC One.
Research partly funded by Neuroblastoma UK leads to an innovative stem cell model providing insight into childhood cancer origins
Researchers from the University of Sheffield and St. Anna Children’s Cancer Research Institute have created a model designed to investigate the origins of neuroblastoma, a cancer primarily affecting infants and young children. The findings offer hope for the creation of tailored treatments which treat aggressive neuroblastomas and minimise the adverse effects experienced by patients from existing therapies.
New research suggests potential combination therapy option for children with neuroblastoma to prevent resistance to treatment
New research published by Professor Suzanne Turner and led by Dr Perla Pucci in her group at the University of Cambridge Department of Pathology and CRUK Cambridge Centre Paediatric Cancer Programme, has suggested a new target for combination treatment of neuroblastoma and other cancers alongside ALK tyrosine kinase inhibitors (ALK TKI). Resistance to ALK TKI is a challenge and so additional targets for treatments that can be used in combination with ALK TKI are urgently needed.
The Power of Collaboration to Find a Cure…
In 2019, Neuroblastoma UK joined forces with childhood cancer charities The Bradley Lowery Foundation and Niamh's Next Step to support more vital research into neuroblastoma.
Ellie’s Memory inspires Aurora to nominate Neuroblastoma UK as the company’s charity partner this year
A big thank you to Aurora, one of the UK’s fastest-growing Print Management, Office Supplies and Telecoms Providers, for choosing Neuroblastoma UK as one of its charity partners for this year.
Charities come together for Teenage and Young Adult Cancer Awareness Month this April
This April marks the second Teenage and Young Adult Cancer Awareness Month, an opportunity for charities and the young people we support to come together and raise awareness of the unique challenges facing this age group when faced with the three words that change their lives: “you have cancer”.
6th Neuroblastoma UK Research Symposium focuses on the biology of neuroblastoma, aiming for more effective and less toxic treatments for children
It was sold out two months in advance, so it was no surprise to see a packed auditorium at Selwyn College Cambridge for the 6th Neuroblastoma UK Research Symposium on 21st and 22nd March 2024. Over 130 scientists and clinicians attended from across Europe, US, and further afield, including world leading experts in pre-clinical and clinical neuroblastoma research.
Encouraging results from the study investigating the role of Enhancer of Zeste homolog 2 (EZH2) and Natural Killer cells in Neuroblastoma
In 2023, Dr Gao, working with Prof Juliet Gray and Dr Zoë Walters at the University of Southampton, aimed to determine the role of natural killer cell- mediated anti-tumour effects in neuroblastoma, after treatment with EZH2. The objectives of the study were to look at the correlation between EZH2 protein expression and the surface expression of natural killer ligands in neuroblastoma cells, and to determine if the natural killer cells induced cytotoxicity that could be enhanced in the neuroblastoma cell lines with EZH2 inhibitors.
Collaboration aims to improve outcomes for children with neuroblastoma
Neuroblastoma UK (NBUK) and Solving Kids’ Cancer UK (SKCUK) have entered into a formal collaboration to speed up the development of new, better treatments for children with neuroblastoma and bring forward the day when no child dies from or because of the disease.
Research Grants - a 2022 update
This year we reviewed the current results of the research initially funded by Neuroblastoma UK from 2010 to 2017. Our Symposiums over the last ten years have brought together researchers to share their work and highlight topics, examples are: new treatments, advances in differentiation therapy, genetic landscape of neuroblastoma , the role of MYC gene and micro RNA signatures.